香港股市 已收市

Adagio Therapeutics, Inc. (ADGI)

NasdaqGM - NasdaqGM 即時價格。貨幣為 USD。
加入追蹤清單
37.07+3.45 (+10.26%)
收市價: 04:00PM EDT
37.07 0.00 (0.00%)
市前: 04:30AM EDT
全螢幕
交易股價資料並非來自所有市場
前收市價33.62
開市34.78
買盤37.00 x 1400
賣出價40.00 x 800
今日波幅34.50 - 38.24
52 週波幅20.50 - 59.50
成交量475,543
平均成交量709,619
市值4.124B
Beta 值 (5 年,每月)
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-31.03
業績公佈日
遠期股息及收益率無 (無)
除息日
1 年預測目標價51.50
  • Benzinga

    Adagio Stock Jumps On Additional Preclinical Data For Its COVID-19 Antibody

    Adagio Therapeutics Inc (NASDAQ: ADGI) has announced new in vitro data demonstrating retained neutralizing activity of ADG20 against a diverse panel of circulating SARS-CoV-2 variants, including the newly emerged Lambda and Mu variants. Related: Adagio's COVID-19 Candidate Shows Prolonged Half-Life, Neutralization At Six Months. Notably, findings show that ADG20 demonstrated potent in vitro neutralizing activity against variants, including those with reduced susceptibility to monoclonal antibody

  • Benzinga

    54 Biggest Movers From Friday

    Gainers Biomerica, Inc. (NASDAQ: BMRA) shares surged 38% to close at $6.21 on Friday. Biomerica entered into a Supplier Agreement with Walmart to sell its EZ Detect colorectal disease screening test within the Walmart retail system. Exscientia Limited (NASDAQ: EXAI) rose 23.2% to settle at $27.10 after the company priced its IPO at $22 per ADS. First Watch Restaurant Group, Inc. (NASDAQ: FWRG) gained 22.9% to close at $22.13 after pricing its IPO at $18 a share. Atea Pharmaceuticals, Inc. (NASDA

  • Benzinga

    35 Stocks Moving In Friday's Mid-Day Session

    Gainers Biomerica, Inc. (NASDAQ: BMRA) shares climbed 38.3% to $6.23. Biomerica entered into a Supplier Agreement with Walmart to sell its EZ Detect colorectal disease screening test within the Walmart retail system. Progenity, Inc. (NASDAQ: PROG) gained 23% to $1.87 after jumping over 40% on Thursday. Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) climbed 21.3% to $42.52 following data from Merck & Co's investigational oral antiviral molnupiravir, which boosted sentiment for Atea Pharmaceutical's AT